Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 4/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL245 | 0.80 | KDM4E (0.59) | KDM4EHSD17B10CYP2C19MAPTLMNA | |
| SCHEMBL28274899 | 0.78 | KDM4E (0.58) | KDM4EHSD17B10CYP2C19MAPTLMNA | |
| SCHEMBL27977550 | 0.78 | KDM4E (0.58) | KDM4EHSD17B10CYP2C19MAPTLMNA | |
| SCHEMBL28276330 | 0.78 | KDM4E (0.58) | KDM4EHSD17B10CYP2C19MAPTLMNA | |
| SCHEMBL28435264 | 0.78 | KDM4E (0.58) | KDM4EHSD17B10CYP2C19MAPTLMNA | |
| SCHEMBL28606591 | 0.78 | KDM4E (0.58) | KDM4EHSD17B10CYP2C19MAPTLMNA | |
| SCHEMBL30442868 | 0.78 | KDM4E (0.58) | KDM4EHSD17B10CYP2C19MAPTLMNA | |
| Water SCHEMBL28988433 | 0.76 | KDM4E (0.56) | KDM4EHSD17B10CYP2C19MAPTLMNA | |
| SCHEMBL28274997 | 0.76 | KDM4E (0.56) | KDM4EHSD17B10CYP2C19MAPTLMNA | |
| Butane SCHEMBL15522319 | 0.76 | KDM4E (0.65) | KDM4EHSD17B10CYP2C19MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093427-B2 | Construction and screening of solution-phase derived library of fenbufen and ethacrynic acid | NATIONAL TSING HUA UNIVERSITY (TW) | 2012-01-10 | — | — | US | disclosed |
| US-20110306668-A1 | CONSTRUCTION AND SCREENING OF SOLUTION-PHASE DERIVED LIBRARY OF FENBUFEN AND ETHACRYNIC ACID | NATIONAL TSING HUA UNIVERSITY (TW) | 2011-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306668-A1 | CONSTRUCTION AND SCREENING OF SOLUTION-PHASE DERIVED LIBRARY OF FENBUFEN AND ETHACRYNIC ACID | CYP4F2, ACR, CYP4F3 | KDM4E 3371/4885HSD17B10 347/4885CYP2C19 480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.